1. Search Result
Search Result
Results for "

deficit

" in MedChemExpress (MCE) Product Catalog:

292

Inhibitors & Agonists

2

Biochemical Assay Reagents

12

Peptides

2

Inhibitory Antibodies

35

Natural
Products

18

Isotope-Labeled Compounds

2

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10295
    SB 202190
    Maximum Cited Publications
    134 Publications Verification

    Organoid p38 MAPK Autophagy Apoptosis Neurological Disease Cancer
    SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .
    SB 202190
  • HY-101872
    GSK-872
    95+ Cited Publications

    RIP kinase Inflammation/Immunology
    GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .
    GSK-872
  • HY-B1462
    Chlorzoxazone
    3 Publications Verification

    Cytochrome P450 Potassium Channel FOXO Amyloid-β Neurological Disease Inflammation/Immunology
    Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates FOXO3 phosphorylation and . Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis .
    Chlorzoxazone
  • HY-17416
    Guanfacine hydrochloride
    3 Publications Verification

    Adrenergic Receptor Cardiovascular Disease Infection Neurological Disease Metabolic Disease
    Guanfacine hydrochloride is an orally active and blood-brain barrier permeability noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine hydrochloride
  • HY-N6608
    Physostigmine
    2 Publications Verification

    Eserine

    Cholinesterase (ChE) Neurological Disease
    Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning .
    Physostigmine
  • HY-17385
    Atomoxetine hydrochloride
    4 Publications Verification

    Tomoxetine hydrochloride; (R)-Tomoxetine hydrochloride; LY 139603

    Adrenergic Receptor Serotonin Transporter Sodium Channel Neurological Disease Cancer
    Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na + channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .
    Atomoxetine hydrochloride
  • HY-B1266
    Physostigmine salicylate
    2 Publications Verification

    Eserine salicylate

    Cholinesterase (ChE) Neurological Disease
    Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning .
    Physostigmine salicylate
  • HY-17416A
    Guanfacine
    3 Publications Verification

    Adrenergic Receptor Cardiovascular Disease Neurological Disease Endocrinology
    Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine
  • HY-B1066
    Butylhydroxyanisole
    5 Publications Verification

    Butylated hydroxyanisole; E320

    Environmental Pollutants Reactive Oxygen Species (ROS) Ferroptosis Neurological Disease Inflammation/Immunology
    Butylhydroxyanisole (Butylated hydroxyanisole) is an antioxidant used as a food additive preservative. Butylhydroxyanisole mediates liver toxicity, retardation in reproductive organ development and learning, and sleep deficit. Butylhydroxyanisole exerts neurotoxic effects and leads to disruption of the brain and nerve development . Butylhydroxyanisole is a ferroptosis inducer .
    Butylhydroxyanisole
  • HY-100611
    CaCCinh-A01
    5+ Cited Publications

    Chloride Channel Inflammation/Immunology Cancer
    CaCCinh-A01 is an inhibitor of both TMEM16A and calcium-activated chloride channel (CaCC) with IC50s of 2.1 and 10 μM, respectively.
    CaCCinh-A01
  • HY-110125
    ML-193
    1 Publications Verification

    CID 1261822

    GPR55 Neurological Disease
    ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .
    ML-193
  • HY-11013

    ST-101

    Calcium Channel nAChR Neurological Disease Cancer
    ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.
    ZSET1446
  • HY-101872A
    GSK-872 hydrochloride
    95+ Cited Publications

    RIP kinase Inflammation/Immunology
    GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .
    GSK-872 hydrochloride
  • HY-N2736
    3′,4′,7-Trihydroxyflavone
    1 Publications Verification

    Beta-lactamase COX Interleukin Related Bacterial JNK ERK p38 MAPK STAT Apoptosis NO Synthase Nuclear Factor of activated T Cells (NFAT) Lactate Dehydrogenase Reactive Oxygen Species (ROS) SOD Akt Caspase Bcl-2 Family Infection Neurological Disease Inflammation/Immunology
    3′,4′,7-Trihydroxyflavone is an orally active inhibitor of OXA-48 (IC50 = 1.89 μM) and COX-1 (IC50 = 36.37 μM). 3′,4′,7-Trihydroxyflavone exhibits antioxidant and anti-inflammatory properties, inhibiting the release of inflammatory cytokines such as IL-6, IL-8, and TNF-α. 3′,4′,7-Trihydroxyflavone inhibits H2O2-induced neuronal apoptosis and ROS accumulation, and exerts anti-neuroinflammatory effects by suppressing the JNK-STAT1 pathway. 3′,4′,7-Trihydroxyflavone exhibits antimicrobial and antibiotic-modifying activities against multidrug-resistant Gram-negative enteric bacteria. 3′,4′,7-Trihydroxyflavone inhibits RANKL-induced osteoclast formation via NFATc1. 3′,4′,7-Trihydroxyflavone activates the CREB-BDNF axis and restores scopolamine (HY-N0296)-induced memory deficits in mice .
    3′,4′,7-Trihydroxyflavone
  • HY-D0873

    EPPS

    Amyloid-β Neurological Disease
    HEPPS (EPPS) is a buffering agent with the useful pH range from 7.3 ~ 8.7. HEPPS reduces -aggregate-induced memory deficits and rescues cognitive deficits in mice. EPPS is orally active and penetrates the blood-brain barrier .
    HEPPS
  • HY-N0541
    Pseudoginsenoside F11
    2 Publications Verification

    Ginsenoside A1

    Endogenous Metabolite Others
    Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.
    Pseudoginsenoside F11
  • HY-W027553

    NIK-247 free base; Amiridine free base

    Cholinesterase (ChE) Potassium Channel Sodium Channel Neurological Disease Metabolic Disease
    Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC50 values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K + and Na +-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .
    Ipidacrine
  • HY-17553
    Coluracetam
    3 Publications Verification

    MKC-231

    iGluR Neurological Disease
    Coluracetam (MKC-231) is an orally taken choline uptake enhancer. Coluracetam can improve the reduced acetylcholine levels in the hippocampus of rats and mice, enhancing learning difficulties, memory deficits, and cognitive impairments. Coluracetam induces a lower degree of hepatic venous hyperglycemia .
    Coluracetam
  • HY-10351A

    NAD-​299 hydrochloride

    5-HT Receptor Neurological Disease
    Robalzotan hydrochloride (NAD-​299 hydrochloride) is a potent and selective 5-Hydroxytryptamine 1A (5-HT1A) inhibitor. Robalzotan hydrochloride increases the firing rate of 5-HT cells. Robalzotan hydrochloride induces 5-HT1A receptor occupancy. Robalzotan hydrochloride has the potential for the research of a cholinergic deficit in the central -nervous system .
    Robalzotan hydrochloride
  • HY-172550

    HCN Channel Neurological Disease
    MS7710 is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor with blood-brain barrier permeability and an excellent brain/plasma concentration ratio. MS7710 inhibits HCN channel-mediated Ih current, and reduces the firing frequency and burst activity of dopaminergic neurons in the ventral tegmental area. MS7710 ameliorates chronic social defeat stress-induced deficits in social interaction and impairments in reward-related cognitive flexibility in mice. MS7710 exerts only limited effects on ventral tegmental area dopaminergic neuron activity, social interaction, exploratory behavior, locomotor activity or sucrose preference in control mice. MS7710 is applicable to the research of major depressive disorder .
    MS7710
  • HY-14880

    JNJ-31001074

    Histamine Receptor Neurological Disease Metabolic Disease
    Bavisant (JNJ-31001074) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. Bavisant can be used for attention-deficit hyperactivity disorder (ADHD) research .
    Bavisant
  • HY-W275295

    PFDoA

    Reactive Oxygen Species (ROS) Caspase Mitochondrial Metabolism Neurological Disease Metabolic Disease
    Perfluorododecanoic acid (PFDoA) is an orally active, blood-brain barrier-permeable perfluorinated compound. Perfluorododecanoic acid increases Caspase 3 activity, disrupts mitochondrial membrane potential, and elevates ROS levels. Perfluorododecanoic acid induces cognitive deficits. Perfluorododecanoic acid exhibits hepatotoxicity .
    Perfluorododecanoic acid
  • HY-116565
    Usmarapride
    1 Publications Verification

    SUVN-D4010

    5-HT Receptor Neurological Disease
    Usmarapride (SUVN-D4010) (Example 3)is a potent, selective, orally active and brain penetrant 5-HT4 receptor partial agonist (EC50=27.5 nM). Usmarapride (SUVN-D4010) can be used for the research of cognitive deficits associated with Alzheimer's disease .
    Usmarapride
  • HY-135869
    Mito-apocynin (C11)
    3 Publications Verification

    Mitochondrial Metabolism Neurological Disease
    Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function .
    Mito-apocynin (C11)
  • HY-P2259
    TAT-GluA2 3Y
    2 Publications Verification

    iGluR Neurological Disease
    TAT-GluA2 3Y, an interference peptide, blocks long-term depression (LTD) at glutamatergic synapses by disrupting the endocytosis of AMPAR. TAT-GluA2 3Y can alleviate Pentobarbital-induced spatial memory deficits and synaptic depression .
    TAT-GluA2 3Y
  • HY-139897

    iGluR Neurological Disease
    CX 717 is a positive allosteric modulator of AMPA receptor. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .
    CX 717
  • HY-W042214

    Ritalinate

    Drug Metabolite Others
    Ritalinic acid (Ritalinate) is the main inactive urinary metabolite of Methylphenidate. Methylphenidate has the potential for attention-deficit hyperactivity disorder and narcolepsy research .
    Ritalinic acid
  • HY-14824

    ABT 894

    nAChR Neurological Disease
    Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD) .
    Sofiniclin
  • HY-107481

    NS 105

    mGluR Neurological Disease
    Fasoracetam (NS 105) is the activator of metabotropic glutamate receptor (mGluR). Fasoracetam (NS 105) has the potential for the research of attention-deficit hyperactivity disorder (ADHD) and Alzheimer's disease (AD) .
    Fasoracetam
  • HY-157999

    Synaptic Vesicle Proteins Neurological Disease
    SDI-118 is an orally active modulator for synaptic vesicle glycoprotein 2A (SV2A) with an IC50 of 13 nM .
    SDI-118
  • HY-B0731A

    SM-9018 free base

    5-HT Receptor Dopamine Receptor Neurological Disease
    Perospirone (SM-9018 free base) is an orally active antagonist of 5-HT2A receptor (Ki=0.6 nM) and dopamine D2 receptor (Ki=1.4 nM), and also a partial agonist of 5-HT1A receptor (Ki=2.9 nM). Perospirone is an atypical antipsychotic agent and has the potential for schizophrenic disease research .
    Perospirone
  • HY-N2320
    Physostigmine hemisulfate
    2 Publications Verification

    Eserine hemisulfate

    Cholinesterase (ChE) Neurological Disease
    Physostigmine hemisulfate (Eserine hemisulfate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine hemisulfate can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine hemisulfate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine hemisulfate is also an antidote for anticholinergic poisoning .
    Physostigmine hemisulfate
  • HY-133712

    Tunodafil

    Phosphodiesterase (PDE) Neurological Disease
    Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .
    Yonkenafil
  • HY-106432A

    SB-202026 hydrochloride; Memric hydrochloride

    mAChR Dopamine Receptor Neurological Disease
    Sabcomeline (SB-202026; Memric) hydrochloride is a muscarinic receptor agonist capable of crossing the blood-brain barrier. Sabcomeline hydrochloride exhibits affinity for all hM1 to hM5 subtypes (pKi=6.72-7.23), and shows near-full agonism at the hM3 receptor, inducing extracellular acidification. Sabcomeline hydrochloride alters the binding kinetics of dopamine D2 receptors through neural network regulation. Sabcomeline hydrochloride also causes minimal cardiovascular changes, effectively reverses spatial memory deficits in rodents and induces conditioned taste aversion. Sabcomeline hydrochloride is an important tool compound in studies of Alzheimer's disease and related neurodegenerative diseases .
    Sabcomeline hydrochloride
  • HY-W391596

    Parasite Infection Neurological Disease
    Pamaquine is an 8-aminoquinoline antimalarial agent. Pamaquine has neurotoxicity and can damage specific neuro-anatomical structures, leading to deficits of neurologic function in Rhesus monkeys models .
    Pamaquine
  • HY-112781

    PF-04958242

    iGluR Neurological Disease
    Pesampator (PF-04958242) is a potent and highly selective positive allosteric modulator of AMPA receptor (an AMPA potentiator) with an EC50 of 310 nM and a Ki of 170 nM .
    Pesampator
  • HY-118342
    PQCA
    1 Publications Verification

    mAChR Neurological Disease
    PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC50 value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease .
    PQCA
  • HY-W415004

    Cholinesterase (ChE) Neurological Disease
    ACHE-IN-38 (Compound mol-8) inhibits the metabolic breakdown of the neurotransmitter acetylcholine (ACh) by the enzyme acetylcholinesterase (AChE) and hence alleviates memory deficits in patients with Alzheimer’s Disease by potentiating cholinergic transmission .
    ACHE-IN-38
  • HY-N0459
    3,5-O-Dicaffeoylquinic acid
    1 Publications Verification

    Others Neurological Disease
    3,5-O-Dicaffeoylquinic acid reverses Trimethyltin-induced learning and memory deficits .
    3,5-O-Dicaffeoylquinic acid
  • HY-15413A

    LY 2216684 hydrochloride

    Serotonin Transporter Neurological Disease
    Edivoxetine (LY 2216684) hydrochloride is a potent and selective norepinephrine reuptake inhibitor. Edivoxetine hydrochloride can be used for the study of major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD) .
    Edivoxetine hydrochloride
  • HY-115383
    Roflupram
    1 Publications Verification

    Phosphodiesterase (PDE) Neurological Disease Inflammation/Immunology
    Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC50 of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors .
    Roflupram
  • HY-165035

    Glucocerebrosides; Gaucher cerebroside; GluCers (gaucher's spleen)

    Endogenous Metabolite Neurological Disease Metabolic Disease
    Glucosylceramides are sphingolipid molecules found in both neuronal and non-neuronal mammalian tissues, as well as in low quantities across various plant species. Elevated levels of glucosylceramides provide cellular protection and prepare certain cells for proliferation; however, they have also been linked to obesity-induced insulin resistance in mice and to neuronal deficits observed in neuronopathic Gaucher disease .
    Glucosylceramide (gaucher's spleen)
  • HY-148325

    nAChR Neurological Disease
    α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .
    α7 Nicotinic receptor agonist-1
  • HY-14880B

    JNJ31001074AAC; JNJ31001074 dihydrochloride hydrate

    Histamine Receptor Neurological Disease Metabolic Disease
    Bavisant (JNJ31001074AAC) dihydrochloride hydrate is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. Bavisant dihydrochloride hydrate can be used for attention-deficit hyperactivity disorder (ADHD) research .
    Bavisant dihydrochloride hydrate
  • HY-149651

    GPR139 Neurological Disease
    GPR139 agonist-2 (compound 20a) is a potent GPR139 agonist with an EC50 of 24.7 nM. GPR139 agonist-2 rescues the social interaction deficits and alleviates cognitive deficits in murine schizophrenia models. GPR139 agonist-2 has the potential for antischizophrenia drug research .
    GPR139 agonist-2
  • HY-115910A

    Interleukin Related Cholinesterase (ChE) Neurological Disease
    Y13g dihydrochloride is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g dihydrochloride reverses the STZ (HY-13753)-induced memory deficit, and shows histopathology similarly as in normal animals .
    Y13g dihydrochloride
  • HY-172876

    iGluR Reactive Oxygen Species (ROS) Trk Receptor Cardiovascular Disease
    FLY26 is a selective partial GluN2B antagonist with an IC50 value of 0.64 μM. FLY26 partially inhibits the GluN2B subunit of NMDA receptors, reduces calcium ion influx and reactive oxygen species (ROS) production and activates the BDNF/TrkB/CREB neuroprotective signaling pathway to alleviate neuronal excitotoxicity and mitochondrial dysfunction. FLY26 is promising for research of neurological deficits caused by cerebral ischemia-reperfusion injury .
    FLY26
  • HY-107676

    nAChR Neurological Disease
    SIB-1553A is an orally bioavailable nicotinic acetylcholine receptors (nAChRs) agonist, with selectivity for β4 subunit-containing nAChRs. SIB-1553A is also a selective neuronal nAChR ligand. SIB-1553A is a cognitive enhancer, and has therapeutic potential for the symptomatic treatment of Alzheimer’s disease and other cognitive disorders .
    SIB-1553A
  • HY-13458A

    L-DOPS hydrochloride; DOPS hydrochloride; SM5688 hydrochloride

    Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
    Droxidopa hydrochloride
  • HY-145559

    KU-596

    HSP Metabolic Disease
    Cemdomespib (KU-596) is a highly bioavailable second-generation Hsp90 modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib induces Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response .
    Cemdomespib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: